US EditionHope S. Rugo, MD, Discusses Retreatment for HER2+ Breast Cancer With Trastuzumab Deruxtecan After ILD
Summary by ajmc.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Hope S. Rugo, MD, Discusses Retreatment for HER2+ Breast Cancer With Trastuzumab Deruxtecan After ILD
New data shed light on the best strategies for managing patients who develop interstitial lung disease (ILD) while being treated with trastuzumab deruxtecan. City of Hope will host a virtual breast cancer forum to review key studies presented at ASCO.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
